KNIGHT THERAPEUTICS INC (GUD.CA) Stock Fundamental Analysis
TSX:GUD - Toronto Stock Exchange - CA4990531069 - Common Stock - Currency: CAD
Taking everything into account, GUD scores 5 out of 10 in our fundamental rating. GUD was compared to 34 industry peers in the Pharmaceuticals industry. GUD has an average financial health and profitability rating. GUD is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
GUD had positive earnings in the past year.
In the past year GUD had a positive cash flow from operations.
In multiple years GUD reported negative net income over the last 5 years.
GUD had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
GUD has a Return On Assets of 1.10%. This is in the better half of the industry: GUD outperforms 80.00% of its industry peers.
GUD has a better Return On Equity (1.39%) than 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.1% | ||
| ROE | 1.39% | ||
| ROIC | N/A |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 2.97%, GUD belongs to the best of the industry, outperforming 82.86% of the companies in the same industry.
GUD's Profit Margin has declined in the last couple of years.
GUD has a better Gross Margin (44.95%) than 68.57% of its industry peers.
GUD's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 2.97% | ||
| GM | 44.95% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
GUD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GUD has been reduced compared to 1 year ago.
Compared to 5 years ago, GUD has less shares outstanding
Compared to 1 year ago, GUD has an improved debt to assets ratio.
2.2 Solvency
GUD has an Altman-Z score of 2.76. This is not the best score and indicates that GUD is in the grey zone with still only limited risk for bankruptcy at the moment.
GUD's Altman-Z score of 2.76 is amongst the best of the industry. GUD outperforms 88.57% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that GUD is not too dependend on debt financing.
GUD has a Debt to Equity ratio of 0.04. This is in the better half of the industry: GUD outperforms 71.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.76 |
ROIC/WACCN/A
WACC9.37%
2.3 Liquidity
GUD has a Current Ratio of 2.97. This indicates that GUD is financially healthy and has no problem in meeting its short term obligations.
GUD has a better Current ratio (2.97) than 74.29% of its industry peers.
A Quick Ratio of 2.06 indicates that GUD has no problem at all paying its short term obligations.
GUD has a better Quick ratio (2.06) than 77.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.97 | ||
| Quick Ratio | 2.06 |
3. Growth
3.1 Past
GUD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 168.75%, which is quite impressive.
Measured over the past years, GUD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.46% on average per year.
Looking at the last year, GUD shows a quite strong growth in Revenue. The Revenue has grown by 12.21% in the last year.
Measured over the past years, GUD shows a very strong growth in Revenue. The Revenue has been growing by 50.87% on average per year.
EPS 1Y (TTM)168.75%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%150%
Revenue 1Y (TTM)12.21%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%2.66%
3.2 Future
GUD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 47.93% yearly.
The Revenue is expected to grow by 9.23% on average over the next years. This is quite good.
EPS Next Y13.52%
EPS Next 2Y29.64%
EPS Next 3Y17.35%
EPS Next 5Y47.93%
Revenue Next Year10.76%
Revenue Next 2Y10.74%
Revenue Next 3Y8.42%
Revenue Next 5Y9.23%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 57.55, which means the current valuation is very expensive for GUD.
Based on the Price/Earnings ratio, GUD is valued a bit cheaper than the industry average as 74.29% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.51, GUD is valued quite expensively.
With a Price/Forward Earnings ratio of 75.33, GUD can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of GUD indicates a somewhat cheap valuation: GUD is cheaper than 68.57% of the companies listed in the same industry.
GUD's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 34.09.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 57.55 | ||
| Fwd PE | 75.33 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GUD indicates a somewhat cheap valuation: GUD is cheaper than 71.43% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 9.69 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
GUD's earnings are expected to grow with 17.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.26
PEG (5Y)N/A
EPS Next 2Y29.64%
EPS Next 3Y17.35%
5. Dividend
5.1 Amount
GUD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:GUD (8/8/2025, 7:00:00 PM)
6.33
-0.07 (-1.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners10.02%
Inst Owner ChangeN/A
Ins Owners1.85%
Ins Owner ChangeN/A
Market Cap630.78M
Analysts78
Price Target7.72 (21.96%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)413.66%
Min EPS beat(2)365.93%
Max EPS beat(2)461.4%
EPS beat(4)2
Avg EPS beat(4)132.08%
Min EPS beat(4)-199.01%
Max EPS beat(4)461.4%
EPS beat(8)4
Avg EPS beat(8)-95.81%
EPS beat(12)7
Avg EPS beat(12)-39.29%
EPS beat(16)8
Avg EPS beat(16)-307.68%
Revenue beat(2)2
Avg Revenue beat(2)4.98%
Min Revenue beat(2)0.88%
Max Revenue beat(2)9.08%
Revenue beat(4)4
Avg Revenue beat(4)4.99%
Min Revenue beat(4)0.88%
Max Revenue beat(4)9.08%
Revenue beat(8)7
Avg Revenue beat(8)4.9%
Revenue beat(12)11
Avg Revenue beat(12)9.21%
Revenue beat(16)14
Avg Revenue beat(16)10.57%
PT rev (1m)0%
PT rev (3m)0.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-26.53%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.08%
Revenue NY rev (1m)0.79%
Revenue NY rev (3m)0.69%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 57.55 | ||
| Fwd PE | 75.33 | ||
| P/S | 1.69 | ||
| P/FCF | N/A | ||
| P/OCF | 69.55 | ||
| P/B | 0.79 | ||
| P/tB | 1.46 | ||
| EV/EBITDA | 9.69 |
EPS(TTM)0.11
EY1.74%
EPS(NY)0.08
Fwd EY1.33%
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)0.09
OCFY1.44%
SpS3.74
BVpS7.98
TBVpS4.34
PEG (NY)4.26
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.1% | ||
| ROE | 1.39% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 2.97% | ||
| GM | 44.95% | ||
| FCFM | N/A |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
F-Score6
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.6 | ||
| Cap/Depr | 46.41% | ||
| Cap/Sales | 6.49% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 18.42% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.97 | ||
| Quick Ratio | 2.06 | ||
| Altman-Z | 2.76 |
F-Score6
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)40.08%
Cap/Depr(5y)130.51%
Cap/Sales(3y)6.77%
Cap/Sales(5y)24.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)168.75%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%150%
EPS Next Y13.52%
EPS Next 2Y29.64%
EPS Next 3Y17.35%
EPS Next 5Y47.93%
Revenue 1Y (TTM)12.21%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%2.66%
Revenue Next Year10.76%
Revenue Next 2Y10.74%
Revenue Next 3Y8.42%
Revenue Next 5Y9.23%
EBIT growth 1Y-220.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year371.57%
EBIT Next 3Y73.66%
EBIT Next 5Y52.72%
FCF growth 1Y-653.06%
FCF growth 3YN/A
FCF growth 5Y23.85%
OCF growth 1Y-71.04%
OCF growth 3Y-6.66%
OCF growth 5Y51.14%